H-reflex in Spastic Lower Limb Cryoneurotomy

Electrophysiological Assessment of Cryoneurotomy in Spastic Lower Limbs.

Spasticity is a common complication after many upper motor neurone disorders. Many surgical techniques have been introduced for patients with refractory spasticity though they are not without peri-operative risks. Cryoneurotomy is another procedure which is cheaper, faster and less invasive in comparison to other surgical interventions. While many studies support the use of cryoneurotomy for pain relief, there are not much studies on use of cryoneurotomy to manage spasticity. The purpose of this study to measure the effect of tibial nerve cryoneurotomy on electrophysiological and clinical spasticity measures in adult patients with spastic equinovarus or equinus foot, who will receive this procedure as a part of their treatment based on spasticity treatment available guidelines. The results will provide us valuable information like how long cryoneurotomy is effective, before regeneration happens.

Study Overview

• Status: Active, not recruiting
• Conditions: Muscle Spasticity
• Intervention / Treatment: Procedure: Cryoneurotomy

Detailed Description

Different surgical techniques, including muscle and tendon lengthening and neurotomy/neurectomy (surgical sectioning of a peripheral nerve) are reserved for patients with refractory spasticity.

Cryoneurotomy which involves direct application of a low temperature probe to a nerve is another procedure, which is cheaper, faster and less invasive than surgical intervention, for the treatment of refractory spasticity. While many studies support using of cold temperature in pain relief (Ilfeld BM, 2017, Friedman, T. 2012), there are not much studies on use of cryoneurotomy to manage spasticity.This clinic has been using cryoneurotomy clinically with empiric success for 2.5 years. The initial results reveal significant increased active and passive range of motion in upper limbs and decreased clonus and improved gait after tibial neurotomy in lower limbs.

Spastic equinovarus foot (SEF) which is a common type of lower limb spasticity is typically treated with focal botulinum toxin injections, bracing and therapeutic exercise, although the drawback of these treatments is the need for serial injections and frequent interactions with health care providers. Recently selective tibial neurotomy has been shown to more definitively treat SEF (Bollens B, et al.2011, Deltombe T, et al. 2015), but as mentioned above this is an invasive approach. In light of our promising clinical experience with cryoneurotomy, we propose to prospectively and systematically measure its effect on SEF, as an alternative to more invasive surgical procedures and the typical multi-modal approach.

The data collection fro this project which is a single-centre, prospective cohort study will occur at the Victoria General Hospital (VGH) multidisciplinary spasticity clinic. Patients with spasticity are referred to this clinic for different procedures including cryoneurotomy. This study will not interfere or change the patients' medical care, and the assessments will be done for the patients who are already candidates for this procedure as a part of their treatment, besides other provided medical cares and have been accepted to receive that.These participants will be invited to have an extra electrophysiological test for being enrolled in this study, which will be performed before the procedure and at 1, 3 and 12 months after cryoneurotomy. In addition, the results of their routine physical examinations including spasticity degree and ankle passive range of motion will be collected in this study.

• Study Type: Observational
• Enrollment (Estimated): 60

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Victoria, British Columbia, Canada, V8Z 6R5
      • Victoria General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Any adult patient with lower limb spasticity who is already candidate for cryoneurotmy as a part of their medical care will be asked to be enrolled in the study.

Description

Inclusion Criteria for patient group:

1. Patients who will have cryoneurotomy as part of their standard treatment for spastic equinovarus foot in VGH spasticity multidisciplinary clinic
2. Adults 18-70 years of age (male and female)
3. Ability to attend testing sessions, comply with testing protocols and provide written informed consent.
4. Able to understand and complete study-related questionnaires (must be able to understand and speak English or have access to an appropriate interpreter as judged by the investigator).

Inclusion Criteria for healthy participants:

1. Any healthy participants with the age between 18 to 70. Over 70 will be excluded due to the expected natural alterations in electrophysiological parameters
2. Able to attend and comply with the testing protocols
3. Able to provide informed written consent
4. Able to understand and speak English or have access to an appropriate interpreter

Exclusion Criteria:

1. History of previous nerve procedures such as chemical neurolysis with alcohol, cryoneurotomy, any surgery of the tibial nerve.
2. Any other neurological pathology different from that responsible for the spasticity.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients; A group pf 30 patients with lower limb spasticity who are already candidate for cryoneurotomy will be invited to have an extra electrophysiological test for participation in this study. The test will be done for both limbs for a better comparison.	Procedure: Cryoneurotomy; Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.; Other Names: nerve cryoablation
Healthy participants; A group of 30 healthy participants will be invited as a control group, and they will have a single session of electrodiagnostic test for their lower limb in dominant side.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Any changes in H max to M max amplitude ratio (H/ M ratio)	The ratio of maximum H reflex amplitude to maximum M wave amplitude as another electrophysiological analog for spasticity will be measured by a commercially available clinical electrodiagnosis machine before the procedure and at 1, 3 and 12 months after it. The results will be presented as a ratio and percentage.	up to 12 months
Changes in maximum H reflex amplitude	The maximum H reflex amplitude as an analog of spasticity as it measure excitability of the monosynaptic reflex arc will be assessed by a commercially available clinical electrodiagnosis machine. The assessment will be done before the procedure and at 1, 3 and 12 months after it and at both sides. The measurement unit will be millivolt (mV).	up to 12 months after procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Degree of changes in ankle dorsi-flexion spasticity as measured by Modified Ashworth Scale (MAS)	MAS has 6 scales from 0 to 4 (0,1,1+,2,3,4) which 0 means no spasticity and 4 means the maximum spasticity and the affected limb is rigid in its position.The assessment will be done by a trained examiner which is not enrolled in providing medical care and will be done before the procedure and at 1, 3 and 12 months after the procedure.	up to 12 months after procedure
Degree of changes in ankle dorsiflexion range of motion	The active and maximum passive dorsiflexion range of motion will be measured by a goniometer and will be presented in degree. The test will be done before and at 1, 3 and 12 months after the procedure by a trained examiner who is not enrolled in providing medical care.	Up to 12 months

Collaborators and Investigators

• Sponsor: Vancouver Island Health Authority

Publications and helpful links

General Publications

• Ilfeld BM, Gabriel RA, Trescot AM. Ultrasound-guided percutaneous cryoneurolysis for treatment of acute pain: could cryoanalgesia replace continuous peripheral nerve blocks? Br J Anaesth. 2017 Oct 1;119(4):703-706. doi: 10.1093/bja/aex142. No abstract available.
• Bollens B, Deltombe T, Detrembleur C, Gustin T, Stoquart G, Lejeune TM. Effects of selective tibial nerve neurotomy as a treatment for adults presenting with spastic equinovarus foot: a systematic review. J Rehabil Med. 2011 Mar;43(4):277-82. doi: 10.2340/16501977-0786.
• Deltombe T, Bleyenheuft C, Gustin T. Comparison between tibial nerve block with anaesthetics and neurotomy in hemiplegic adults with spastic equinovarus foot. Ann Phys Rehabil Med. 2015 Apr;58(2):54-9. doi: 10.1016/j.rehab.2014.12.003. Epub 2015 Jan 9.
• Friedman T, Richman D, Adler R. Sonographically guided cryoneurolysis: preliminary experience and clinical outcomes. J Ultrasound Med. 2012 Dec;31(12):2025-34. doi: 10.7863/jum.2012.31.12.2025.

Study record dates

Study Major Dates

• Study Start (Actual): December 15, 2020
• Primary Completion (Estimated): September 1, 2023
• Study Completion (Estimated): November 1, 2023

Study Registration Dates

• First Submitted: May 25, 2021
• First Submitted That Met QC Criteria: May 25, 2021
• First Posted (Actual): May 28, 2021

Study Record Updates

• Last Update Posted (Actual): June 5, 2023
• Last Update Submitted That Met QC Criteria: June 1, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: spasticity; Range of motion; H reflex; Lower limb; Cryoneurotomy
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Musculoskeletal Diseases; Muscular Diseases; Neuromuscular Manifestations; Muscle Hypertonia; Muscle Spasticity
• Other Study ID Numbers: H20-02294

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No